Dr Louis E Kleager, MD in Ketchikan, AK - Otolaryngology

Dr Louis E Kleager, MD is a Otolaryngology physician based in Ketchikan, Alaska. Dr Louis E Kleager is licensed to practice in Alaska (license number 5251) and his current practice location is 212 Carlanna Lake Rd, Suite 201, Ketchikan, Alaska. He can be reached at his office (for appointments etc.) via phone at (907) 228-7611.

NPI number for Dr Louis E Kleager is 1770645350 and his current mailing address is 212 Carlanna Lake Rd, Suite 201, Ketchikan, Alaska. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1770645350.

Contact Information

	Dr Louis E Kleager, MD
	212 Carlanna Lake Rd, Suite 201, Ketchikan, AK 99901-5613
	(907) 228-7611
	(907) 247-3306

Physician's Profile

Full Name	Dr Louis E Kleager
Gender	Male
Speciality	Otolaryngology
Location	212 Carlanna Lake Rd, Ketchikan, Alaska
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1770645350
Provider Enumeration Date: 12/13/2006
Last Update Date: 03/07/2023

Medical Identifiers

Medical identifiers for Dr Louis E Kleager such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1770645350	NPI	-	NPPES
31763	Other	NE	BCBSNE PPO
6520210	Medicaid	SD
10025334000	Medicaid	NE
31763	Other	NE	BCBS NON PPO #
5251	Other	AK	MEDICAL LICENSE #
91174982300	Medicaid	NE
91174982301	Medicaid	NE
MD5055	Medicaid	AK
13222	Other	NE	STATE MEDICAL LICENSE #
8556	Other	NE	MIDLANDS CHOICE GROUP

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207Y00000X	Otolaryngology	5251 (Alaska)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Louis E Kleager is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Louis E Kleager, MD 212 Carlanna Lake Rd, Suite 201, Ketchikan, AK 99901-5613 Ph: (907) 228-7611	Dr Louis E Kleager, MD 212 Carlanna Lake Rd, Suite 201, Ketchikan, AK 99901-5613 Ph: (907) 228-7611

News Archive

VA health system scrutiny draws headlines

Howard and Jean Somers have been meeting with VA officials and congressional staffers to tell their son's story. "If your system is so difficult to get into," Howard Somers asked, "how the hell are you going to prevent suicides?" ... (Daniel's) service in Iraq, including multiple combat missions as a turret gunner, left him with severe post-traumatic stress disorder and traumatic brain injury.

Dialysis patients gather to encourage state lawmakers to support Medigap legislation

More than 50 dialysis patients, family members and kidney care advocates from across South Carolina gathered at the state Capitol today with the National Kidney Foundation Serving the Carolinas, South Carolina Region (NKF) and Dialysis Patient Citizens (DPC) to encourage state lawmakers to support Medigap legislation (S. 1128, sponsored by Senators Harvey Peeler (R-Cherokee) and Phillip Shoopman (R-Greenville), and H. 4552, sponsored by Representatives Joan Brady (R-Richland), Bill Sandifer (R-Seneca) and Kristopher Crawford (R-Florence)).

Neuralstem announces results from Phase I trial using NSI-566 spinal cord stem cells in treatment of ALS

Neuralstem, Inc. (NYSE MKT: CUR) announced that the final results from the Phase I safety trial using NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) were published in the peer-reviewed journal, "Annals of Neurology".

Mylan enters into agreement with Gilead Sciences to manufacture, distribute Tenofovir Alafenamide

Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited has entered into an agreement with Gilead Sciences, Inc. under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide (TAF) as both a single agent product and in combination with other drugs.

Radiation therapy plays a crucial role in management of OPSCC

HPV-negative UM-SCC4 with and without transfection of HPV E6 oncoprotein, HPV-negative UPCI-SCC-089, and HPV-positive UPCI-SCC-099 cell lines were used in this study.

Dr Louis E Kleager, MD - Otolaryngology in Ketchikan, AK